From: Metabolic syndrome and increased susceptibility to renal cell carcinoma – a meta-analysis
Random-effects model | Fixed-effects model | Heterogeneity | Heterogeneity between groups | |||||
---|---|---|---|---|---|---|---|---|
Analysis | N | HR (95%CI) | P | HR (95%CI) | P | I2 | Ph | P |
Subgroup 1: PC | 7 | 1.50 (1.33, 1.70) | < 0.001 | 1.57 (1.51, 1.62) | < 0.001 | 79.00% | < 0.001 | < 0.001 |
RC | 3 | 1.34 (1.27, 1.41) | < 0.001 | 1.34 (1.27, 1.41) | < 0.001 | 0.00% | 0.606 | |
Subgroup 2: man | 6 | 1.47 (1.26, 1.72) | < 0.001 | 1.51 (1.46, 1.56) | < 0.001 | 89.50% | < 0.001 | 0.068 |
woman | 4 | 1.42 (1.32, 1.53) | < 0.001 | 1.42 (1.35, 1.51) | < 0.001 | 25.00% | 0.261 | |
Subgroup 3: BMI | 2 | 1.43 (1.29, 1.58) | < 0.001 | 1.49 (1.45, 1.53) | < 0.001 | 86.60% | < 0.001 | 0.707 |
WC | 8 | 1.53 (0.90, 2.59) | 0.113 | 1.58 (1.16, 2.15) | 0.004 | 65.00% | 0.091 | |
Subgroup 4: UK | 2 | 1.31 (1.02, 1.69) | 0.032 | 1.28 (1.12, 1.47) | < 0.001 | 67.90% | 0.078 | 0.022 |
China | 3 | 1.63 (1.01, 2.63) | 0.045 | 1.84 (1.44, 2.35) | < 0.001 | 63.30% | 0.066 | |
Korea | 5 | 1.43 (1.28, 1.60) | < 0.001 | 1.49 (1.45, 1.54) | < 0.001 | 89.70% | < 0.001 | |
Subgroup 5: Follow-up ≥ 10 | 5 | 1.35 (1.05, 1.74) | 0.021 | 1.34 (1.18, 1.51) | < 0.001 | 67.70% | 0.016 | 0.071 |
Follow-up < 10 | 5 | 1.47 (1.32, 1.64) | < 0.001 | 1.50 (1.45, 1.54) | < 0.001 | 89.90% | < 0.001 |